Adimab announces new partnerships, milestones

USA-based therapeutic antibody developer Adimab said it has entered into definitive agreements with several new companies, as well as expanded partnerships with several of its current partners.

Guy Van Meter, vice president of business development at Adimab, said: “In addition to welcoming new partners, we take tremendous pride in generating longer-term relationships with our existing partners. Most of Adimab’s existing partners have sought to expand their relationships beyond the initial terms of the engagement; recently expanded partnerships include those with Five Prime, Innovent Biologics, Acceleron, Potenza, Jounce Therapeutics, Surface Oncology, and Alector.”

Adimab also announced that it has recently achieved technical milestones with several partners, including Merck & Co, Acceleron Pharmaceuticals, Kite Pharma, Surface Oncology, and Potenza Therapeutics. Merck has recently exercised a commercial license under one of its earlier agreements and Arsanis Biosciences has initiated a Phase I clinical study in healthy volunteers.